You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

CLINICAL TRIALS PROFILE FOR CLARITIN-D 24 HOUR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Claritin-d 24 Hour

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00550550 ↗ Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Completed ALK-Abelló A/S Phase 3 2007-11-01 The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00550550 ↗ Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2007-11-01 The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00562159 ↗ Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) Completed ALK-Abelló A/S Phase 3 2007-11-01 This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Claritin-d 24 Hour

Condition Name

Condition Name for Claritin-d 24 Hour
Intervention Trials
Healthy 5
Allergic Rhinitis 3
Rhinitis, Allergic, Seasonal 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Claritin-d 24 Hour
Intervention Trials
Rhinitis 9
Rhinitis, Allergic 7
Rhinitis, Allergic, Seasonal 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Claritin-d 24 Hour

Trials by Country

Trials by Country for Claritin-d 24 Hour
Location Trials
United States 36
Canada 4
Ukraine 1
Brazil 1
Serbia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Claritin-d 24 Hour
Location Trials
New Jersey 4
Kentucky 4
Michigan 2
Massachusetts 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Claritin-d 24 Hour

Clinical Trial Phase

Clinical Trial Phase for Claritin-d 24 Hour
Clinical Trial Phase Trials
Phase 4 9
Phase 3 4
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Claritin-d 24 Hour
Clinical Trial Phase Trials
Completed 21
Terminated 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Claritin-d 24 Hour

Sponsor Name

Sponsor Name for Claritin-d 24 Hour
Sponsor Trials
Merck Sharp & Dohme Corp. 5
Ranbaxy Laboratories Limited 4
Bayer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Claritin-d 24 Hour
Sponsor Trials
Industry 23
Other 10
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Claritin-D 24 Hour: Clinical Trials, Market Analysis, and Projections

Introduction to Claritin-D 24 Hour

Claritin-D 24 Hour is a combination medication that includes loratadine, an antihistamine, and pseudoephedrine sulfate, a decongestant. This formulation is designed to provide relief from the symptoms of allergic rhinitis, including nasal congestion, runny nose, and other associated symptoms.

Clinical Trials and Efficacy

Comparative Efficacy Studies

In a double-blind, placebo-controlled, multicenter study, Claritin-D 24 Hour was compared to Claritin-D 12 Hour and placebo in treating patients with moderate-to-severe seasonal allergic rhinitis (SAR). The study involved 469 patients and showed that both Claritin-D 24 Hour and Claritin-D 12 Hour were significantly superior to placebo in reducing total, nasal, and nonnasal symptom scores[3].

  • Symptom Relief: Patients treated with Claritin-D 24 Hour and Claritin-D 12 Hour experienced significant relief from rhinorrhea and nasal stuffiness compared to those receiving the placebo.
  • Onset of Action: Claritin-D starts to work in as little as 30 minutes, providing quicker relief compared to intranasal steroids (INS) which can take up to 12 hours for relief and up to 14 days to reach maximum efficacy[1].

Safety Profile

The same study highlighted the safety profile of Claritin-D 24 Hour:

  • Insomnia: Claritin-D 24 Hour produced significantly less insomnia (4%) compared to Claritin-D 12 Hour (15%) and placebo (2%)[3].
  • Dry Mouth: Both Claritin-D 24 Hour and Claritin-D 12 Hour had similar rates of dry mouth (13%), which was higher than the placebo group (4%)[3].

Market Analysis

Market Size and Growth

The Claritin market, which includes Claritin-D 24 Hour, is projected to grow significantly in the coming years. As of 2023, the Claritin market size was valued at $0.16 billion and is expected to reach $0.26 billion by 2031, growing at a CAGR of 5.67% during the forecast period 2024-2031[2].

Market Drivers

Several factors drive the growth of the Claritin market:

  • Product Innovation: Ongoing research and development lead to novel formulations, such as extended-release variants and combination medicines, which appeal to consumers seeking improved convenience and efficacy[2].
  • Alterations in Lifestyle Factors: Urban living and increased exposure to allergens like pollen, dust mites, and pet dander contribute to higher demand for allergy treatments[2].
  • Seasonal Demand: Seasonal allergies, particularly in spring and autumn, increase the demand for allergy relief medicines like Claritin-D 24 Hour[2].
  • Promotions and Marketing: Effective marketing strategies enhance brand awareness and stimulate sales[2].

Geographical Segmentation

The Claritin market is segmented geographically into several key regions:

  • North America: The United States and Canada have significant market penetration due to strong brand recognition and high prevalence of allergic conditions[2].
  • Europe: Countries like Germany and the UK show substantial demand driven by rising pollen levels and increased awareness about allergic rhinitis[2].
  • Asia-Pacific: This region is emerging as a significant market due to a growing population, urbanization, and higher disposable income[2].
  • Latin America and Middle East & Africa: These regions are witnessing a gradual rise in acceptance and demand for allergy medications, including Claritin-D 24 Hour[2].

Market Projections

Growth Potential

The global loratadine market, which includes Claritin-D 24 Hour, was valued at $153.4 million in 2023 and is expected to grow at a CAGR of 2.9% from 2024 to 2030. This growth is driven by the high prevalence of allergies worldwide, changing lifestyles, and a favorable regulatory landscape[5].

Online Pharmacy Segment

The online pharmacy segment is expected to grow at the fastest CAGR during the forecast period. This is due to the increasing adoption of online platforms, which offer large availability, accessibility, affordable pricing, and integration with telemedicine services[5].

Key Players

The major players in the Claritin market include:

  • Bayer AG
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • Merck

These companies play a crucial role in the development, marketing, and distribution of Claritin-D 24 Hour, contributing to its market presence and growth[2].

Challenges and Opportunities

Challenges

  • Competition from Generic Brands: The presence of generic loratadine products at reduced pricing can constrain the market share of branded Claritin-D 24 Hour[2].
  • Market Saturation: The presence of numerous established antihistamine medicines can lead to market saturation, complicating growth efforts[2].
  • Adverse Effects and Consumer Reservations: Possible side effects, such as dry mouth, and consumer reservations about traditional drugs may hinder widespread acceptance[2].

Opportunities

  • Global Expansion: Expanding into new markets and regions can augment the consumer base and potential revenue for Claritin-D 24 Hour[2].
  • Product Innovation: Continuous innovation in formulations and delivery methods can attract more consumers seeking improved convenience and efficacy[2].

Key Takeaways

  • Clinical Efficacy: Claritin-D 24 Hour is clinically proven to provide significant relief from allergic rhinitis symptoms, with a quicker onset of action compared to other treatments.
  • Market Growth: The Claritin market, including Claritin-D 24 Hour, is projected to grow at a CAGR of 5.67% from 2024 to 2031.
  • Geographical Expansion: The market is expanding globally, with significant growth potential in regions like Asia-Pacific and Latin America.
  • Challenges and Opportunities: While facing competition from generic brands and market saturation, there are opportunities for growth through product innovation and global expansion.

FAQs

Q: What are the active ingredients in Claritin-D 24 Hour?

A: Claritin-D 24 Hour contains loratadine, an antihistamine, and pseudoephedrine sulfate, a decongestant.

Q: How quickly does Claritin-D 24 Hour start to work?

A: Claritin-D 24 Hour starts to work in as little as 30 minutes[1].

Q: What are the common side effects of Claritin-D 24 Hour?

A: Common side effects include dry mouth and, less frequently, insomnia compared to the 12-hour formulation[3].

Q: What is the projected market size of Claritin by 2031?

A: The Claritin market is projected to reach $0.26 billion by 2031, growing at a CAGR of 5.67% from 2024 to 2031[2].

Q: Which regions are expected to see significant growth in the Claritin market?

A: The Asia-Pacific region, along with Latin America and the Middle East & Africa, are expected to see significant growth due to increasing population, urbanization, and higher disposable income[2].

Sources

  1. Claritin-D® Efficacy - Claritin.com
  2. Claritin Market Size, Share, Growth, Trends & Forecast - Verified Market Research
  3. Comparative efficacy and safety of once-daily versus twice-daily Claritin-D in the treatment of patients with seasonal allergic rhinitis - PubMed
  4. Claritin® Efficacy - Claritin.com
  5. Loratadine Market Size, Share, Growth, Trends Report, 2030 - Grand View Research
Last updated: 2025-01-07

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.